In vitro analyzes of the action of hyaluronic acid (HA)-coated and uncoated nanostructured lipid carriers (CLN) on cervical cancer and normal cells

Abstract

Cervical cancer is one of the leading gynecological cancers worldwide, being considered the third most commonly diagnosed cancer type and the fourth leading cause of cancer death in women. As alternative treatments there are, surgery, chemotherapy, radiotherapy and brachytherapy, these being most often used together. But approximately 35% of women diagnosed with cervical cancer have recurrent disease, with 90% of these findings within three years after initial treatment. As a result, target therapies and chemo and radiotherapies strategies are essential for reducing mortality, highlighting the research and development of nanotherapies that could provide greater efficacy and / or reduction of undesired toxicity in the treatment of cancer. And among research, great potential for more local therapy, nanostructured lipid carriers (CLN) and hyaluronic acid (HA) is seen. The aim of this work was to investigate the interaction and internationalization of lipid nanoparticles (coated and uncoated with hyaluronic acid) on morphology, proliferation, cytotoxicity, cell migration and apoptosis, observing how nanoparticles act and how they work alterations may participate in the tumorigenic process. Therefore, a strain will be used squamous cell cervical carcinoma (SiHa) and a normal cell line (HaCaT) to be treated with lipid nanoparticles (CLN) uncoated and coated with hyaluronic acid (HA). So we can understand some of the mechanisms and interactions of these nanoparticles, with tumor cells of cervical cancer and normal cells.